Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa". Mohr-Holland, E.; Reuter, A.; Hughes, J.; Daniels, J.; Beko, B.; Makhanda, G.; De Avezedo, V.; Kock, Y.; Cox, H.; Furin, J.; Trivino Duran, L.; Isaakidis, P.; and Ferlazzo, G. jul, 2020.
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa" [link]Paper  doi  abstract   bibtex   
Here we report on the final outcomes for the cohort of 103 patients, 77% HIV-positive with a median (interquartile range, IQR) CD4 count of 141 (61–252) cells per mm3, from Khayelitsha, South Africa who initiated regimens containing delamanid (Dlm) for the treatment of rifampicin-resistant tuberculosis (RR-TB) from November 2015 to August 2017 [1]. The median (IQR) duration on Dlm was 6.3 (4.3–12.0) months; 54 (52%) patients received Dlm for more than 6 months and 32 (31%) also received a regimen containing bedaquiline (Bdq), 26 (81%) of whom harboured fluoroquinolone (Fq) resistant strains. Delamanid (Dlm) containing regimens to treat RR-TB are effective, but more data on Dlm use is needed. Dlm remains an important treatment option in programmatic settings with high rates of HIV co-infection and in persons with limited treatment options. \textlesshttps://bit.ly/3cVLeUq\textgreater
@misc{Mohr-Holland2020,
abstract = {Here we report on the final outcomes for the cohort of 103 patients, 77{\%} HIV-positive with a median (interquartile range, IQR) CD4 count of 141 (61–252) cells per mm3, from Khayelitsha, South Africa who initiated regimens containing delamanid (Dlm) for the treatment of rifampicin-resistant tuberculosis (RR-TB) from November 2015 to August 2017 [1]. The median (IQR) duration on Dlm was 6.3 (4.3–12.0) months; 54 (52{\%}) patients received Dlm for more than 6 months and 32 (31{\%}) also received a regimen containing bedaquiline (Bdq), 26 (81{\%}) of whom harboured fluoroquinolone (Fq) resistant strains. Delamanid (Dlm) containing regimens to treat RR-TB are effective, but more data on Dlm use is needed. Dlm remains an important treatment option in programmatic settings with high rates of HIV co-infection and in persons with limited treatment options. {\textless}https://bit.ly/3cVLeUq{\textgreater}},
author = {Mohr-Holland, Erika and Reuter, Anja and Hughes, Jennifer and Daniels, Johnny and Beko, Busisiwe and Makhanda, Goodman and {De Avezedo}, Virginia and Kock, Yulene and Cox, Helen and Furin, Jennifer and {Trivino Duran}, Laura and Isaakidis, Petros and Ferlazzo, Gabriella},
booktitle = {European Respiratory Journal},
doi = {10.1183/13993003.00837-2020},
file = {:C$\backslash$:/Users/Claire/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Mohr-Holland et al. - 2020 - Correspondence regarding Delamanid for rifampicin-resistant tuberculosis a retrospective study from South A.pdf:pdf},
issn = {13993003},
keywords = {OA,fund{\_}ack,letter},
mendeley-tags = {OA,fund{\_}ack,letter},
month = {jul},
number = {1},
pages = {2000837},
pmid = {32703820},
publisher = {NLM (Medline)},
title = {{Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"}},
url = {https://erj.ersjournals.com/content/56/1/2000837 https://erj.ersjournals.com/content/56/1/2000837.abstract},
volume = {56},
year = {2020}
}
Downloads: 0